GlassScriptPhysician profile
Mona Shah
NPI 1659329308
$3,581.89
in general payments reported to CMS, 2019-2025
26 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $492 · 2021: $562 · 2022: $560 · 2023: $808 · 2024: $657 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $648.26 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $580.50 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $381.72 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $207.02 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $190.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $184.20 | 2019-2024 | |
| Abbott Laboratories | $166.44 | 2021-2023 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.03 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $135.35 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $124.48 | 2021-2023 | Verquvo |
| Medtronic Vascular, INC. | $101.17 | 2020 | |
| Baxter Healthcare | $92.39 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $83.59 | 2019-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $80.82 | 2019-2024 | Wainua, Farxiga |
| Esperion Therapeutics, INC. | $78.21 | 2023-2024 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $75.78 | 2021 | |
| Cvrx, INC. | $67.39 | 2021-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $55.41 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.23 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.58 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.35 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.13 | 2024 | Arcalyst |
| Genzyme Corporation | $18.85 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.15 | 2021 | |
| Kestra Medical Technology Services, INC. | $15.88 | 2025 | Assure Wcd |
| Allergan, INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.